Alcon Inc. (ALC) Sees Mixed Signals After Q1 Beat and Target Reduction

We recently compiled a list of the 8 Most Oversold Large Cap Stocks to Buy. Alcon Inc. (NYSE:ALC) is one of the most oversold stocks on this list.

TheFly reported on May 8 that ALC saw its valuation outlook revised as Barclays reduced the price target to $78 from $90 while reiterating an Equal Weight rating on the shares.

Separately, on May 5, Alcon Inc. (NYSE:ALC) reported its first-quarter 2026 performance, showing strong underlying momentum across its eye care portfolio. Sales reached $2.7 billion, increasing 10% on a reported basis and 6% in constant currency compared with the prior year period. Growth was supported by new product launches in both surgical and vision care segments, including advanced intraocular lens platforms and contact lens innovations, along with strength in dry eye treatments.

wavebreakmedia/Shutterstock.com

The corporation’s core operating income rose year over year, reflecting improved efficiency and higher sales volumes, although reported operating income declined due to investments in new product commercialization, tariffs, and restructuring-related costs. Core earnings per share increased to $0.85, while reported EPS was $0.39, affected by prior-year investment gains. Cash generation remained stable, with operating cash flow improving modestly. The company also maintained shareholder returns through a dividend and authorized a new $1.5 billion share repurchase program.

Alcon Inc. (NYSE:ALC) is a global eye care company based in Geneva and the world’s largest in ophthalmic devices. It provides surgical and vision care products for conditions like cataracts, glaucoma, and retinal diseases, serving patients in over 140 countries.

READ NEXT: 10 Best Cancer Stocks to Buy for the Long Term and 10 Most Popular Stocks on Robinhood in 2026.

Disclosure: None. Follow Insider Monkey on Google News.